Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 9 - Medicinal preparations characterised by special physical form
Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
10/2003
10/30/2003WO2002060474A3 Mixtures of mushroom enzymes and the use thereof for treating maldigestion
10/30/2003WO2002060406A8 Veterinary dermatologic composition
10/30/2003WO2002060405A8 Veterinary dermatologic composition comprising a sphingoid base and/or a sphingoid base derivative
10/30/2003WO2002020090A9 Pharmaceutical compositions
10/30/2003WO2002015962A3 Apparatus and method for delivery of drugs or gene therapy vasculature
10/30/2003WO2001051054A3 Use of cyclopentenone derivatives for bone and periodontal regeneration
10/30/2003US20030204180 Temperature responsive delivery systems
10/30/2003US20030204165 Ultrasonic septum monitoring for implantable medical devices
10/30/2003US20030204023 Providing a mixture comprising the polymeric material and a monomer comprising a first catechol group and reactive group; oxidizing mixture; polymerizing monomer via the first catechol group and reactive group to form polymer
10/30/2003US20030203976 Anti-angiogenic compositions and methods of use
10/30/2003US20030203970 Bronchodilators; adrenergic agonists; side effect reduction
10/30/2003US20030203968 Levothyroxine compositions and methods
10/30/2003US20030203967 Levothyroxine compositions having unique Tmax properties
10/30/2003US20030203964 Process for producing medicaments which comprise HMG CoA reductase inhibitors
10/30/2003US20030203961 A taxane joined by a hydrolyzable bond to one or more oligomers that containing a polyethylene glycol group and a tert-amide group
10/30/2003US20030203958 Therapeutic inhibitor of vascular smooth muscle cells
10/30/2003US20030203953 Repinotan kit
10/30/2003US20030203952 Novel processes for making- and a new crystalline form of- leflunomide
10/30/2003US20030203937 Use in treating medical disorders such as depression, obsessive compulsive disorder, and panic
10/30/2003US20030203930 Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
10/30/2003US20030203925 Use in the treatment of respiratory tract diseases
10/30/2003US20030203903 Administering a rifamycin microbiocides for treating infections caused by Mycobacterium tuberculosis, Mycobacterium avium complex, Chlamydia pneumoniae or Helicobacter pylori
10/30/2003US20030203878 Comprises non-hydrated hydrogel, superdisintegrant, and tannic acid; for treatment of metastatic bone diseases (hypercalcemia)
10/30/2003US20030203876 Comprises epothilone in form of infusion concentrate or lyophilised composition
10/30/2003US20030203874 Revitalization formulation
10/30/2003US20030203871 Novel cationic cholesteryl derivatives containing cyclic polar groups
10/30/2003US20030203865 Lipid-comprising drug delivery complexes and methods for their production
10/30/2003US20030203854 Composition for effecting serum cholesterol levels
10/30/2003US20030203850 Transdifferentiation of pancreatic acinar cells
10/30/2003US20030203849 Composition promoting lacrimal secretion
10/30/2003US20030203842 Apolipoprotein A-l agonists and their use to treat dyslipidemic disorders
10/30/2003US20030203697 For percutaneous administration of a drug other than 2-amino-1-(2',5'- dimethoxyphenyl)ethanol or its salt
10/30/2003US20030203206 Allows a substance incorporated therein to be controllably released
10/30/2003US20030203098 For solid pharmaceutical dosage units, such as tablets; comprising a subcoat, an optional colorcoat, and a polish coat; good dissolution, appearance, taste
10/30/2003US20030203052 Superoxide dismutase-containing cucumber extract coated and/or microencapsulated in a fat-soluble agent based on a fatty substance can be used by the topical or oral route; antiallergens; sunscreen agents; foods; drugs; cosmetics
10/30/2003US20030203050 Combining a wetted active agent with dry silicified microcrystalline cellulose (MCC) in a dryer to form agglomerated particles and incorporating these particles into solid dosage form; neutraceuticals
10/30/2003US20030203048 Oral administration to counteract dehydration resulting from vomiting, diarrhea, physical exercise or illness; especially suitable for infants, small children and the elderly; water, sodium, potassium, citrate, carbonate and structuring
10/30/2003US20030203046 Solutions and aerosols of metal-containing compounds
10/30/2003US20030203044 Wound-treating gel
10/30/2003US20030203040 Controlled release microencapsulated NGF formulation
10/30/2003US20030203039 Preparation of microparticles having a selected release profile
10/30/2003US20030203038 Targeted delivery of bioactive factors to the systemic skeleton
10/30/2003US20030203037 Dosage forms which can be administered parenterally and comprise a suspension of the salt of tramadol and diclofenac
10/30/2003US20030203036 Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
10/30/2003US20030203034 Compositions for treating hyperemia
10/30/2003US20030203033 Biodegradation organophosphorus polymer; administering to tumor in situ
10/30/2003US20030203032 Dilute aqueous solution containing epidermal growth factor in gel
10/30/2003US20030203031 Immune modulation with polystyrene sulfonate
10/30/2003US20030203030 Polymeric gel delivery system for pharmaceuticals
10/30/2003US20030203029 Controlled release liquid active agent formulation dosage forms
10/30/2003US20030203028 Multiplex drug delivery system suitable for oral administration
10/30/2003US20030203027 Coating technique for deposition of drug substance on a substrate
10/30/2003US20030203026 Compressed tablet containing non-steroid antiinflammatory drug
10/30/2003US20030203025 Sustained release oral formulations
10/30/2003US20030203024 Hydrogel-forming sustained-release preparation
10/30/2003US20030203023 Once-a-day administering synergistic mixture
10/30/2003US20030203022 Quick disintegrating tablet in buccal cavity and production process thereof
10/30/2003US20030203021 Pharmaceutical compositions containing epinastine and pseudoephedrine
10/30/2003US20030203020 Pharmaceutical compositions for piperidinoalkanol compounds
10/30/2003US20030203019 Coated conditioners for use in foods and pharmaceuticals
10/30/2003US20030203018 Stable oral pharmaceutical dosage forms
10/30/2003US20030203017 Plaster for topical use containing heparin and diclofenac
10/30/2003US20030203016 Nutrients, cosmetics, drugs; algae culture product
10/30/2003US20030203015 Absorber substrate coated with ointment
10/30/2003US20030203013 Microbial cellulose wound dressing for treating chronic wounds
10/30/2003US20030203007 Pharmaceutical composition reduced in bitter taste and the like
10/30/2003US20030203003 Drug releasing biodegradable fiber implant
10/30/2003US20030203001 Drug delivery; analgesics, antiinflammatory agents; contacting skin with hydrogel containing drugs
10/30/2003US20030203000 Modulation of therapeutic agent release from a polymeric carrier using solvent-based techniques
10/30/2003US20030202995 Transdermal drug delivery
10/30/2003US20030202994 Excitatory amino acid inhibitors for treating sensitive skins
10/30/2003US20030202979 Mixture of lecithin and polymer
10/30/2003US20030202978 Spray freeze-dried compositions
10/30/2003US20030202960 Therapeutic angiogenic factors and methods for their use
10/30/2003US20030202944 Carrier particles for use in dry powder inhalers
10/30/2003US20030202936 PH sensitivity; releasing drugs
10/30/2003US20030200899 Colored hard capsules
10/30/2003CA2770411A1 Aerosol containing a particulate active substance
10/30/2003CA2482719A1 Conjugates of membrane translocating agents and pharmaceutically active agents
10/30/2003CA2482249A1 Dry powder inhalant composition
10/30/2003CA2482193A1 Moisture triggered release systems comprising aroma ingredients providing fragrance burst in response to moisture
10/30/2003CA2482183A1 Method of treating biological materials with translating electrical fields and electrode polarity reversal
10/30/2003CA2482037A1 Condom
10/30/2003CA2481972A1 Methods of treating ileus
10/30/2003CA2481524A1 Method of inhibiting restenosis
10/30/2003CA2481467A1 Dry powder compositions
10/29/2003EP1357184A2 Novel cis-element decoys useful as anti-tumor therapeutics
10/29/2003EP1356826A1 Microparticles comprising carbohydrate beads covalently linked with allergen
10/29/2003EP1356825A1 Process for producing aqueous cellulose derivative dispersion
10/29/2003EP1356823A2 Use of skin penetration enhancers and barrier disruption agents to enhance transcutaneous immune response induced by ADP-ribosylating exotoxin
10/29/2003EP1356822A2 Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens
10/29/2003EP1356821A2 Use of skin penetration enhancers and barrier disruption agents to enhance transcutaneous immune response INDUCED BY ADP-RIBOSYLATING EXOTOXIN
10/29/2003EP1356816A1 Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient
10/29/2003EP1356814A1 Pharmaceutical emulsion preparation
10/29/2003EP1356811A1 Preventives or remedies for arthritis
10/29/2003EP1356809A1 Sustained release preparations
10/29/2003EP1356808A2 Coating technique for deposition of drug substance on a substrate
10/29/2003EP1356807A2 Method for converting sparingly water-soluble medical substance to amorphous state
10/29/2003EP1356806A1 A pharmaceutical composition for treating dysmenorrhea and premature labor
10/29/2003EP1355965A2 Block copolymers for multifunctional self-assembled systems
1 ... 2074 2075 2076 2077 2078 2079 2080 2081 2082 2083 2084 2085 2086 2087 2088 2089 2090 2091 2092 2093 2094 ... 2991